• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过表达修饰的抗原靶向受体介导的内化途径的树突状细胞诱导强烈的辅助性和细胞毒性T细胞以及B细胞反应。

Induction of vigorous helper and cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway.

作者信息

You Z, Huang X F, Hester J, Rollins L, Rooney C, Chen S Y

机构信息

Center for Cell and Gene Therapy, Department of Molecular and Human Genetics, and Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.

出版信息

J Immunol. 2000 Oct 15;165(8):4581-91. doi: 10.4049/jimmunol.165.8.4581.

DOI:10.4049/jimmunol.165.8.4581
PMID:11035100
Abstract

Efficient Ag presentation is essential to induce effective cellular and humoral immune responses. Thus, one central goal of current immunotherapy and vaccine development is to enhance Ag presentation to induce potent and broad immune responses. Here, a novel Ag presentation strategy is developed by transducing dendritic cells (DCs) to produce an Ag for presentation as an exogenous Ag to efficiently induce both humoral and cellular immunity. The principle of this strategy is illustrated by genetically modifying DCs to secrete a model hepatitis B virus Ag fused with a cell-binding domain and to process the fusion Ag as an exogenous Ag after receptor-mediated internalization for MHC class I and II presentation. Vigorous Ag-specific CD4(+) helper and CD8(+) cytotoxic T cell, as well as B cell, responses were induced by the transduced DCs in mouse models. Thus, this novel strategy uses a receptor-mediated internalization process to efficiently induce all arms of the adaptive immunity and may provide a powerful means to develop potent vaccines and immunotherapies.

摘要

高效的抗原呈递对于诱导有效的细胞免疫和体液免疫反应至关重要。因此,当前免疫治疗和疫苗开发的一个核心目标是增强抗原呈递以诱导强大而广泛的免疫反应。在此,通过转导树突状细胞(DCs)以产生一种抗原作为外源性抗原进行呈递,从而开发出一种新型的抗原呈递策略,以有效诱导体液免疫和细胞免疫。该策略的原理通过对DCs进行基因改造得以阐明,使其分泌与细胞结合域融合的乙型肝炎病毒模型抗原,并在受体介导的内化后将融合抗原作为外源性抗原进行加工,用于MHC I类和II类呈递。在小鼠模型中,转导的DCs诱导了强烈的抗原特异性CD4(+)辅助性T细胞和CD8(+)细胞毒性T细胞以及B细胞反应。因此,这种新型策略利用受体介导的内化过程有效诱导适应性免疫的所有分支,可能为开发强效疫苗和免疫疗法提供有力手段。

相似文献

1
Induction of vigorous helper and cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway.通过表达修饰的抗原靶向受体介导的内化途径的树突状细胞诱导强烈的辅助性和细胞毒性T细胞以及B细胞反应。
J Immunol. 2000 Oct 15;165(8):4581-91. doi: 10.4049/jimmunol.165.8.4581.
2
Targeting dendritic cells to enhance DNA vaccine potency.靶向树突状细胞以增强DNA疫苗效力。
Cancer Res. 2001 May 1;61(9):3704-11.
3
A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses.一种通过树突状细胞将细胞内肿瘤抗原作为外源性抗原呈递的逆转录策略可诱导有效的抗肿瘤辅助性T细胞和细胞毒性T淋巴细胞反应。
Cancer Res. 2001 Jan 1;61(1):197-205.
4
Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.经逆转录病毒转导的骨髓来源树突状细胞需要CD4 + T细胞的辅助来引发保护性和治疗性抗肿瘤免疫。
J Immunol. 1999 Jan 1;162(1):144-51.
5
Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.树突状细胞对外源抗原的MHC I类呈递的诱导由CD4 + T细胞控制,这些T细胞在富含胆固醇的结构域中与II类分子结合。
J Immunol. 2002 Feb 1;168(3):1172-80. doi: 10.4049/jimmunol.168.3.1172.
6
Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells.逆转录病毒转导的小鼠树突状细胞需要CD4 + T细胞辅助来引发抗肿瘤免疫:对树突状细胞临床应用的启示
J Immunol. 2000 Feb 1;164(3):1243-50. doi: 10.4049/jimmunol.164.3.1243.
7
Characterization of humoral and CD4+ cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens.用表达不同形式乙肝病毒核心抗原和e抗原的逆转录病毒载体进行基因免疫后体液和CD4 +细胞反应的特征分析
J Virol. 1997 Jul;71(7):5295-303. doi: 10.1128/JVI.71.7.5295-5303.1997.
8
The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens.与肿瘤抗原融合的志贺毒素B亚基可引发细胞毒性T淋巴细胞(CTL)反应,并靶向树突状细胞,以实现I类主要组织相容性复合体(MHC)限制的外源性抗原衍生肽的呈递。
J Immunol. 2000 Sep 15;165(6):3301-8. doi: 10.4049/jimmunol.165.6.3301.
9
Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.通过将缺乏MHC II类分子的树突状细胞与肿瘤细胞融合诱导抗肿瘤免疫受损。
J Immunol. 2005 Feb 1;174(3):1274-80. doi: 10.4049/jimmunol.174.3.1274.
10
Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design.用重组腺病毒载体感染小鼠骨髓来源的树突状细胞会导致编码抗原通过MHC I类和II类分子呈递,这在疫苗设计中具有潜在益处。
Vaccine. 2002 Dec 13;21(3-4):231-42. doi: 10.1016/s0264-410x(02)00448-6.

引用本文的文献

1
Challenges and opportunities in mRNA vaccine development against bacteria.抗细菌mRNA疫苗开发中的挑战与机遇。
Nat Microbiol. 2025 Aug;10(8):1816-1828. doi: 10.1038/s41564-025-02070-z. Epub 2025 Jul 29.
2
A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention.一种用于癌症免疫治疗和免疫预防的新型抗PD-L1疫苗。
Cancers (Basel). 2019 Dec 1;11(12):1909. doi: 10.3390/cancers11121909.
3
Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity.
靶向活性转录因子 XBP1s 至树突状细胞可增强疫苗诱导的预防性和治疗性抗肿瘤免疫。
Mol Ther. 2012 Feb;20(2):432-42. doi: 10.1038/mt.2011.183. Epub 2011 Sep 20.
4
ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.免疫刺激复合物佐剂在体内将免疫激活与抗原递呈给树突状细胞相结合,从而有效诱导 CD8+ T 细胞的交叉呈递。
J Immunol. 2011 Jul 1;187(1):55-63. doi: 10.4049/jimmunol.1004114. Epub 2011 May 25.
5
Transcriptional IL-15-directed in vivo DC targeting DNA vaccine.转录因子 IL-15 靶向的体内树突状细胞 DNA 疫苗。
Gene Ther. 2009 Oct;16(10):1260-70. doi: 10.1038/gt.2009.110. Epub 2009 Sep 3.
6
Targeting hepatitis B virus antigens to dendritic cells by heat shock protein to improve DNA vaccine potency.通过热休克蛋白将乙肝病毒抗原靶向树突状细胞以提高DNA疫苗效力。
World J Gastroenterol. 2007 Nov 28;13(44):5911-7. doi: 10.3748/wjg.v13.i44.5911.
7
Study on biological characters of SGC7901 gastric cancer cell-dendritic cell fusion vaccines.SGC7901胃癌细胞-树突状细胞融合疫苗的生物学特性研究
World J Gastroenterol. 2006 Jun 7;12(21):3438-41. doi: 10.3748/wjg.v12.i21.3438.
8
Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination.用于疫苗接种的含35型纤维的腺病毒载体评估。
Mol Ther. 2006 Apr;13(4):756-65. doi: 10.1016/j.ymthe.2005.12.008. Epub 2006 Feb 7.
9
SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling.细胞因子信号转导抑制因子1(SOCS1)通过调节白细胞介素-12(IL-12)的产生和信号传导,限制树突状细胞打破自身耐受性并诱导抗肿瘤免疫的能力。
J Clin Invest. 2006 Jan;116(1):90-100. doi: 10.1172/JCI26169. Epub 2005 Dec 15.
10
Dendritic cells and the handling of antigen.树突状细胞与抗原处理
Clin Exp Immunol. 2003 Nov;134(2):178-80. doi: 10.1046/j.1365-2249.2003.02279.x.